Expression of HERV-K GAG and ENV, p-ERK and p16 in neval and melanoma specimens [8]
1. Introduction
Human endogenous retroviruses (HERVs) are thought to be germline-integrated genetic remnants of exogenous retroviral infections and comprise approximately 8% of the human genome [1, 2]. Similar to exogenous retroviruses such as human immunodeficiency virus (HIV) and human T cell leukemia virus (HTLV), a complete HERV sequence is composed of GAG, POL, and ENV genes flanked by two long terminal repeats (LTRs). Although most HERVs are degenerated with disruptive open reading frames, a few proviruses have retained intact genes, and the corresponding proteins can thus be expressed [1, 3]. HERVs have been implicated in the etiology of cancer, chronic inflammation, and other diseases [2], and emerging data support a role of HERV-K in melanomagenesis. For example, HERV-K is activated in melanomas but not in melanocytes [4, 5], and inhibition of HERV-K by RNA interference (RNAi) suppresses the
2. The K type Human Endogenous Retroviral Element (HERV-K)
HERVs are thought to be germline-integrated genetic remnants of exogenous retroviral infections and comprise approximately 8% of the human genome [1,2]. They are transmitted vertically by Mendelian inheritance [12]. HERVs can be classified into over 20 families based on transfer RNA (tRNA) specificity of the primer binding site used to initiate reverse transcription; thus, HERV-K would use lysine and HERV-W tryptophan if they were replicating viruses [13]. Through millions of years of evolution, HERVs have become indispensible parts of the human genome. For example, syncytin-1, encoded by the envelope (ENV) gene of HERV-W, mediates intercellular fusion of trophoblast cells to form syncytiotrophoblast as well as preventing maternal immune attack against the developing embryo, thereby facilitating implantation of the embryo [1,2]. Similar to exogenous retroviruses such as human immunodeficiency virus (HIV) and human T cell leukemia virus (HTLV), a complete HERV sequence is composed of group-specific antigen (GAG), polymerase (POL), and ENV genes flanked by two long terminal repeats (LTRs) (Fig. 1). Although most HERVs are degenerated with disruptive open reading frames, a few proviruses have retained intact genes, and the corresponding proteins can thus be expressed [1, 3]. Increased HERV expression has been found under pathological conditions, particularly in cancer and inflammatory disease [12, 14]. Unlike most HERVs that harbor defective mutations, the HML-2 group of HERV-Ks has open reading frames that code for functional viral proteins, which may form noninfectious particles [15, 16]. HERV-K proteins and virus-like particles have been demonstrated in human cell lines of teratocarcinoma [17], breast cancer [18], placenta [19], and melanoma [5].
HERVs have been implicated in the etiology of cancer, chronic inflammation, and other diseases [2], and emerging data support a role of HERV-K in melanomagenesis. For example, HERV-K is activated in melanomas but not in melanocytes [4, 5], and inhibition of HERV-K by RNAi suppresses the
Like functional retrovirus, HERV-K transcripts can retro-transpose and insert back to the host genome, depending on the insertion sites, may lead to mutagenesis. The enzymes encoded by HERV-K may also induce retro-transposition of Long-interspersed nuclear element-1 (LINE-1) elements, as in the case of HIV-1 [22]. We designed experiment to determine HERV-K genomic integration sequences by HERV-K anchored polymerase chain reaction (PCR). The PCR amplicons can be sequenced after subcloning of individual sequences or next generation sequencing (NGS).
We designed and performed preliminary experiments as shown in Fig. 2. DNA was extracted from human cells using QIAamp® DNA Mini kit (Qiagen, Valencia, CA) following manufacturer’s procedures. The optical density (OD) values of DNA were measured before samples were stored at -80°C for further use. Primers used (based on HERV-K108, accession # AF164614) were: 5’3’: GCG GTC CCA AAA GGG TCA GTN NNN NNN NNN; 5’ERV (nucleotide 2156-): TTT GCC AGA ATC TCC CAA TC; 3’ERV (nucleotide 4063-): TTG AGC CTT CGT TCT CAC CT; 5’Tag: GCG GTC CCA AAA GGG TCA GT. To perform PCR, about 75ng DNA from human cells was amplified with 0.3 μM 5’3’ and 5’ERV or 3’ERV primers, 0.4 mM dNTPs, 1X Pfx Buffer, 1mM MgSO4, and 1.25 unit Platinum® Pfx DNA Polymerase (Invitrogen, Carlsbad, CA). The PCR reaction was carried out in a 9700 thermocycler (Applied Biosystem, Carlsbad, CA). Initial denaturing was at 94°C for 5 minutes, then 94°C for 15 seconds, 36°C for 30 seconds, and 68°C for 4 minutes, for 35 cycles, with an extension at 68°C for 10 minutes after the last cycle. Then 10 μl of the PCR products were used for the 2nd PCR using 5’Tag and 5’ERV or 3’ERV primers with the same amplification conditions except 55°C for annealing. The 2nd PCR products were purified using the QIAquick PCR Purification Kit (Qiagen Inc., Valencia, CA). The resulting templates can be sequenced after subcloning or directly by next generation sequencing.
In a recent study, Macfarian etc shown that during embryogenesis, transcripts of embryonic and extraembryonic tissues are initiated from long terminal repeats derived from endogenous retroviruses [21]. It is conceivable that HERV-K LTR may also regulate gene transcription during melanomagenesis, a hypothesis that can be tested in future studies. The experimental strategy used in Fig. 2 may also apply to determine transcripts downstream of HERV-K sequences.
As with some other viruses, syncytium formation is a characteristic of retroviral infection. As shown in Fig. 3B, pleomorphic cells with features of nuclear atypia, multinuclear/nuclear syncytia are characteristic of malignant cells. We hypothesize that HERV-K mediated intercellular fusion contributes to the formation of pleomorphic cells in tumor specimens.
We performed experiments to identify fusogenic domains and epitopes in HERV-K ENV protein, and to generate HERV-K ENV monoclonal antibodies and evaluate for ability to block ENV mediated intercellular fusion. The fusogenic activity of syncytin has been located to its N-terminus [23]. To map fusogenic domains of HERV-K ENV protein, we will generate a series of C-terminal truncations of HERV-K ENV by PCR using HERV-K108 sequence as template. PCR amplicons will be cloned into pcDNA 3.3-TOPO TA Mammalian Expression Vector using TA Cloning Kit (Invitrogen, Grand Island, NY). The ENV expression constructs will be transfected into melanoma cells and examined for activities to rescue fusogencity inhibited by HERV-K inhibition.
3. Possible regulation of HERV-K by BRAF-MEK and p16-CDK4
We noticed that the growth characteristics of melanoma cells that can be modified by HERV-K activation (e.g., changes in cell shape, loss of melanin, anchorage-independent growth) [9] overlap with those that can be blocked by suppression of BRAF-MEK-ERK signaling pathway, especially with simultaneous restoration of p16 or inhibition of CDK4 [23-26]. This observation, together with the knowledge that aberrations in BRAF-MEK-ERK and p16-CDK4 pathways are early events and often co-exist during melanomagenesis, and the evidence that RAF-MEK-ERK signaling pathway is required for the completion of HIV-1 reverse transcription [27], prompted us to hypothesize that HERV-K is regulated by BRAF-MEK-ERK and p16-CDK4 pathways. We have reported that expression of HERV-K GAG and ENV proteins correlates with ERK activation and p16 loss in a panel of melanocytic specimens, and that inhibition of MEK and CDK4, especially in combination, suppresses HERV-K protein expression in cultured melanoma cells [11].
Seventy two formalin-fixed, paraffin-embedded pathological specimens were available from the archives at the University of Texas Medical Branch (UTMB). The samples included 38 nevi (11 junctional, 3 compound, and 24 dermal) and 34 melanomas (10 Lentigo maligna, 10 superficial spreading, 7 nodular, and 7 metastatic). The study was approved by the UTMB institutional review board (IRB) for the protection of human subjects. Immunohistochemical staining was modified from the protocol of All-in-One Kit for Immunohistochemical Staining for Tissues with Antibodies (Invitrogen, Carlsbad, CA). Four-micron-thick sections of paraffin blocks were dewaxed in three changes of xylene and rehydrated through a graded series of alcohol concentrations into water. Sections were washed with PBS Tween (PBST) (Sigma, St Louis) three times, each for 5 minutes, then blocked with horse serum for 30 minutes at room temperature. For antigen retrieval, sections were heat-treated in a microwave oven for 20 minutes in 0.01 M citrate buffer (pH 6.0, 100 mM stock), and cooled for 20 minutes in a beaker. For immunostaining the slides were incubated at 4 ℃ overnight with primary antibodies including phospho-p44/42 ERK (Thr202/Tyr204,Cat. #9101, Cell Signaling Technology, Danvers, MA), p16 (Cat. #MS-887 NeoMarkers, Fremont, CA), HERV-K GAG and ENV (Cat. #s 1841-5 and 1811-5, respectively, Austral Biologicals, San Ramon, CA) following the manufacturer’s instructions. The slides were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies, followed by signal development, counterstaining and mounting using All-in-One Kit for Immunohistochemical Staining for Tissues with Antibodies (Invitrogen, Carlsbad, CA). As described previously [28], blood vessel were stained distinctly for p-ERK and used as an internal control for p-ERK antibody. Epidermal keratinocytes and adnexal glands were internal controls for p16 [28]. Melanoma cell line A375 was reported positive for HERV-K using the same HERV-K antibodies [9], and was used as positive control for HERV-K GAG and ENV antibodies, as described [11].
As shown in Fig. 3 [11], we examined the expression of HERV-K GAG and ENV proteins, the active form of ERK (phospho-ERK, p-ERK), and p16 in a panel human melanocytic specimens including 38 benign nevi and 34 melanomas. Both HERV-K GAG and ENV proteins were largely cytoplasmic, but occasional nuclear staining was observed, whereas p-ERK was typically co-expressed in cytoplasm and nucleus. It has been reported that wild-type
|
|
|
|
|
|
||
HERV-K GAG, cytoplasmic | 3 | 38 |
|
HERV-K GAG, nuclear | 0 | 6 |
|
HERV-K ENV, cytoplasmic | 11 | 44 |
|
HERV-K ENV, nuclear | 8 | 12 |
|
p-ERK, cytoplasmic and nuclear | 13 | 68 |
|
p16, cytoplasmic | 79 | 50 |
|
p16, nuclear | 79 | 15 |
|
Further analysis showed that the expression of HERV-K GAG in the cytoplasm of melanoma was positively correlated with p-ERK (
|
|
|
||
p-ERK, cytoplasmic and nuclear |
|
|
|
|
p16, cytoplasmic |
|
|
|
|
p16 |
|
|
|
|
As described [11], human melanoma cell lines 624Mel, A101D, A375, and OM431 were kindly provided by Dr. Stuart Aaronson (Mount Sinai School of Medicine, New York, NY). Cells were maintained in Dulbecco's modified Eagle medium (DMEM, Mediatech, Herndon, VA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma, St. Louis, MO) and 50 units/mL penicillin-streptomycin (Invitrogen, Carlsbad, CA) in a humidified incubator at 37 °C with 5% CO2. Total RNA was extracted from cultured melanoma cells using an RNA extraction kit ToTALLY RNA (Ambion, Austin, TX) according to the manufacturer’s instructions, and purified with RNase free DNase Set (Qiagen, Valencia, CA). RNA concentration was assessed spectrophotometrically at 260/280 nm. Two µg of total RNA was reverse transcribed and amplified by One-Step RT-PCR (Qiagen, Valencia, CA) using 50 pmol of primer pairs specific for HERV-K POL, ENV genes and GAPDH for control as described [9]. Briefly, samples were reverse transcribed at 50 C for 30 min, then heat-activated by incubation at 95 C for 15 min. Samples were subjected to 30 cycles of PCR amplification as described [9] in MasterCycler® Personal (Eppendorf, Hamburg, Germany). Each cycle consisted of 1 min at 95 C, 1 min at 56 C and 1 min at 72 C. After the final cycle, samples were incubated at 72 °C for 10 min. PCR products were inspected by separation through 1% agarose gels. PCR products were purified using QIAquick PCR Purification Kit (Qiagen, Valencia, CA). The purified PCR products were directly sequenced on both strands using a 3100 Capillary Array Sequencer and Big Dye Terminator Chemistry (Applied Biosystems, Foster City, CA). NCBI BLAST search of the human genome was performed to identify the amplified sequences [11].
Western blots were performed as described [24, 11]. Briefly, harvested cells were lysed in Lysis Solution (Cell Signaling, Danvers, MA) supplemented with Complete Mini Protease Inhibitor Cocktail Tablets (Roche Diagnostics Corporation, Indianapolis, IN). Protein concentration of lysates was determined using the Quick Start Bradford 1 x Dye Reagent (Bio-Rad, Hercules, CA). Lysates were separated in 10% SDS-polyacrylamide gel, electrophoretically transferred to Immobilon-P membrane (Millipore Corp, Billerica, MA), and probed with primary antibodies followed by incubation with horseradish peroxidase-conjugated secondary antibodies. The following antibodies were used: phospho-p44/42 ERK (Thr202/Tyr204) and p44/42 ERK (Cell Signaling, Danvers, MA), PhosphoPlus(R) RB (Ser780, Ser795, Ser807/811) Antibody Kit (Cell Signaling, Boston, MA), HERV-K GAG and ENV (Cat. #s1841-5 and 1811-5, respectively, Austral Biologicals, San Ramon, CA), and HRP-conjugated secondary antibodies (Jackson Immunoresearch, West Grove, PA). Immunoreactive bands were visualized with SuperSignal chemiluminescence substrate (Pierce, Rockford, IL). The blots were exposed to blue sensitive blue x-ray film (Phenix Research, Candler, NC).
MEK inhibitor PD98059 (Calbiochem, San Diego, CA) was dissolved in DMSO as a 50 mM stock solution, aliquoted and stored in –20 °C. CDK4 inhibitor 219476 (Cat. #219476, Calbiochem, San Diego, CA) was dissolved in DMSO as a 2 mM stock solution and stored at 4 °C. 1×106 melanoma cells were seeded in a cell culture dish in DMEM containing 10% FBS and antibiotics. On the second day, cells were treated with PD98059 and 219476 in DMEM without serum for 48 h and then harvested. Statistical analyses were performed by using SPSS 13.0 software (SPSS Inc., Chicago, IL). Fisher exact test was used to detect the differences in immunostaining between melanomas and nevi. Pearson Correlation was used to test the correlations of immunostaining (HERV-K GAG, HERV-K ENV, p-ERK, and p16).
The expression of HERV-K has been reported in several melanoma cell lines [4, 5, 9, 30]. We examined HERV-K in four melanoma cell lines, 624Mel, A375, A101D, and OM431 that have constitutive activation of p-ERK, and loss of wild-type p16 with corresponding hyper-phosphorylation of RB protein [24, 25, 26]. As previously reported [11], HERV-K expression was detected using a specific HERV-K ENV antibody as described [5, 9], that recognizes a 37 Kd spliced transmembrane domain of ENV protein [4, 5, 30]. HERV-K ENV protein was prominently expressed in 624Mel and A375 cells, weakly positive in A101D cells, but barely detectable in OM431 cells (Fig. 4A). We extracted total cellular RNA from all the four cell lines and performed conventional RT-PCR using specific HERV-K POL and ENV primers as described [9]. Direct sequencing of RT-PCR amplicons and NCBI BLAST analysis showed that the expressed sequences share 96%-98% overall homology with Group N HERV-K [31] (data not shown), as reported in other melanoma cells [32].
We have established experimental conditions (including time course and dose-response curve) of treating several melanoma cells with PD98059 and 219476, to respectively inhibit MEK and CDK4, alone and in combination [26]. 624Mel and A375 lines were used to test whether HERV-K EVE expression was suppressed by the MEK and CDK4 inhibitors. As expected, treatment with PD98059 inhibited ERK phosphorylation in both 624Mel and A375 cells (Fig. 4B, lane 2). It is worth noting that we consistently observed somewhat further reduced levels of p-ERK by PD98059 when combined with CDK4 inhibition (Fig. 4B, p-ERK, lane 4 vs. lane 2; also in Li et al., 2009, Fig. 1a, lane 4 vs. lane 2); which may contribute to the observed functional interaction between BRAF-MEK-ERK and p16-CDK4-RB pathways [25, 26]. Phosphorylation of serine 780, a CDK4 target in the RB protein, was reduced by PD98059 and 219476, especially in combination in both cell lines (Fig. 4B). Similarly, HERV-K ENV expression was inhibited by either PD98059 or 219476, especially when used in combination (Fig. 4B). The results were consistent with findings of the association between HERV-K expression and p-ERK and p16 in melanocytic specimens (Table 2).
Multiple endogenous and exogenous factors have been linked to the activation of HERVs including hormones, cytokines, and cytotoxic chemicals [33]. To our knowledge, a direct association between ERK and p16-CDK4 pathways and HERV expression has only been reported by our group [11]. It has been shown that HERV-K sequences, as other host genes, are regulated by DNA methylation in the promoter/enhancer sequences located in the 5’-LTR regions [34]. Since RB protein, a downstream mediator of BRAF-MEK-ERK and p16-CDK4 signaling pathways, is a key regulator of DNA methylation [35], it is conceivable that the observed association between HERV-K, p-ERK and p16-CDK4 may act through RB, a notion that will surely prompt further investigation. It is worth noting that the four melanoma cell lines examined, 624Mel, A375, A101D and OM431, all have
HERV-K may prove to be a key mediator of BRAF-MEK-ERK and p16-CDK4-RB pathways during melanoma pathogenesis. Activation of BRAF/ERK was recently shown to drive chromosome abnormality and aneuploidy in melanocytes [36]. It is conceivable that the effect may be mediated, at least partly, through HERV-K sequences that are capable of jumping around by retro-transposition leading to mutagenesis and chromosomal abnormalities [8, 20]; HERV-K proteins have been shown to suppress the host immune system [6]. Activation of HERV-K by BRAF-MEK-ERK and CDK4 signaling may facilitate tumor progression especially in the blood/lymph stream when circulating tumor cells are under attack by the immune system, thus providing a critical survival/escape mechanism for invasion and metastasis [12, 37]. Alternatively, it is possible that the observed growth promotion and anti-apoptotic effects of activated ERK and CDK4 [25, 26] can be mediated, at least in part, by HERV-K since HERV-K has been shown to directly affect melanoma cell proliferation, differentiation, and anchorage related survival [7, 9].
4. Combined inhibition of CDK4 potentiate the effect of MEKi
Constitutive dysregulation of MEK-ERK and p16-CDK4-RB pathways both occur at high frequencies in melanoma. We found that simultaneous inhibition of both MEK and CDK4 generated more potent and dramatic lethal effects than individual inhibition in melanoma cells [10, 25, 38]. We also found that the expression of K- type human endogenous retrovirus (HERV-K) correlates with ERK activation and p16 loss in melanoma cells and that inhibition of MEK and CDK4 can block HERV-K expression [11]. As shown in Fig. 5, if HERV-K drives tumor progression downstream of RAF-MEK-ERK and p16/CDK4, when HERV-K is already turned on, cells may escape the inhibitory effects of therapies targeting RAF-MEK-ERK and p16/CDK4. Given that HERV may drive malignant growth downstream of MEK and CDK-4, we hypothesized that cells with activated HERV may not respond to the therapeutic effects of MEK and CDK4 blockers and that triple therapy, such as targeting HERV-K, MEK and CDK4, may be necessary to produce more effective and long-lasting therapeutic effects than single or, as we have proposed previously, double inhibition of MEK-ERK and CDK4 [25, 26]. This strategy is analogous to HIV “cocktail” therapy that disrupts HIV at different steps of replication and brought many AIDS patients from death to fairly normal and productive lives [39].
|
|
1 | solvent control |
2 | solvent control + BRAFi/MEKi |
3 | solvent control + CDK4i |
4 | solvent control + BRAFi/MEKi + CDK4i |
5 | HERV-Ki + solvent control |
6 | HERV-Ki + BRAFi/MEKi |
7 | HERV-Ki + CDK4i |
8 | HERV-Ki + BRAFi/MEKi + CDK4i |
We designed experiments to examine the effects of combined inhibition of HERV-K, BRAF/MEK, and CDK4 in melanoma cells (Table 3). Human melanoma cell lines MeWo, A101D and A375 that harbor wild-type, heterozygote, and loff of heterozygosity (LOH)
We performed experiments to simultaneously inhibit MEK and CDK4 using known pharmacological inhibitors PD98059 and 219476, respectively, along with using azidothymidine (AZT) to target HERV-K reverse transcription activity as described [42]. AZT (also called ZDV) is a nucleoside analog reverse-transcriptase inhibitor (NRTI), a type of antiretroviral drug used for the successful treatment of HIV infection. It is a therapeutic analog of thymidine. Optimal results were obtained when cultured A101D and 624Mel cells were treated for a period of 48 hours (Fig. 6). A decrease in the number of viable cells was observed for both A101D and 624Mel cells. The data from this study provided preliminary data of the effect AZT has on melanoma cells in combination with inhibitors of MEK and CDK4, in support of our hypothesis and our rationale for using AZT as a complementary treatment. Several follow-up studies will be performed. The effects of the chemical treatment on melanoma cells, e.g., cell proliferation, apoptosis, and cell cycle progression will be measured using established methods [10, 38]. Molecular mediators of the effects (phospho-ERK, phospho-RB, HERV proteins) will be measured using commercial available antibodies by Western blotting. Future studies are also necessary to further investigate the regulation and activities of HERV-K in melanoma pathogenesis.
We have learnt the significance of “contaminating DNA” in the measurement of HERV-K expression from our recent investigation of the correlation between HERV-K expression and HIV-1 viral load in plasma specimens [Esqueda et al., in press]. We performed RNA extraction using HIV-1 ViroSeq RNA preparation method (Abbott Molecular, Des Plaines, IL). According to the manufacturer this RNA preparation kit extracts total nucleic acid including RNA plus DNA (Dr. Gavin Cloherty, personal communication). According to Qiagen, “The QIAamp Viral RNA Mini Kit is not designed to separate viral RNA from cellular DNA, and both will be purified in parallel if present in the sample” (page 9, QIAamp Viral RNA Mini Handbook, 04/2010). We used DNase I digestion to effectively remove contaminating cellular DNA in the RNA samples. As demonstrated in Fig. 7, without DNase I digestion, HERV-K RT-PCR was uniformly positive in all five HIV-1 positive plasma specimens, whereas only samples #3 and #5 were positive after DNase I digestion. The results emphasize that optimized methodology in the laboratory is essential to the accurate assessment of HERV-K activation.
5. Conclusion
Constitutive dysregulation of MEK-ERK and p16-CDK4-RB pathways both occur at high frequencies in melanoma. We found that simultaneous inhibition of both MEK and CDK4 generated more potent and dramatic lethal effects than individual inhibition did, in melanoma cells. It has been shown recently that the K-type human endogenous retroviral sequence (HERV-K) is expressed in melanoma cells but not in melanocytes. HERVs are germline-integrated genetic remnants of retroviral infections that are transmitted vertically by Mendelian inheritance. It is estimated that 8% of the human genome consists of retroviral elements including HERVs (4). HERVs can be classified to over 20 families based on tRNA specificity of the primer binding site used to initiate reverse transcription. HERV sequences are similar to the HIV sequence. HERV-K activation was observed to be correlated with changes in growth characteristics of melanoma cells (e.g., changes in cell shape, loss of melanin, anchorage- independent growth. We have shown that the expression of HERV-K correlates with ERK activation and p16 loss in melanoma cells and that inhibition of MEK and CDK4 can block HERV-K expression. Given that HERV may drive malignant growth downstream of MEK and CDK-4, we hypothesized that cells with activated HERV may not respond to the therapeutic effects of MEK and CDK4 blockers and that triple inhibition of MEK, CDK4, and HERV should be more effective than double treatment, a hypothesis supported by our preliminary data. Additional studies are necessary to further examine the regulatory relationship between aberrant MEK-ERK and p16-CDK4-RB pathways and HERV-K activation, the roles and mechanisms of HERV-K in carcinogenesis and clonal evolution of malignant cells. The potential therapeutic efficacy of triple inhibition of BRAF-MEK, CDK4, and HERV-K need to be further explored in our fight against melanoma and other malignancies.
Nomenclature
AIDS: acquired immune deficiency syndrome
Alu:
BRAFi: BRAF inhibitor
CDK4: cyclin-dependent kinase 4
CDK4i: CDK4 inhibitor
DMEM: Dulbecco's modified Eagle medium
DNA: deoxyribonucleic acid
ENV: envelop
ERK: extracellular-signal-regulated kinase
FBS: fetal bovine serum
FDA: Food and Drug Administration
FGF: fibroblast growth factor
FISH: fluorescent
GAG: group-specific antigen
HERV: human endogenous retroviruse
HERV-K: K-type human endogenous retrovirus
HIV: human immunodeficiency virus
HTLV: human T cell leukemia virus
IHC: immunohistochemical staining
LINE-1: long-interspersed nuclear element-1
LOH: loss of heterozygosity
LTR: long terminal repeatRs
MEK: mitogen-activated protein kinase/ERK kinase
MEKi: MEK inhibitor
NGS: next generation sequencing
OD: optical density
PAGE: polyacrylamide gel electrophoresis
PARP: poly (ADP-ribose) polymerase
PBS: phosphate buffered saline
PCR: polymerase chain reaction
p-ERK: phopho-ERK
PI3K: phosphatidylinositol 3-kinase
POL: polymerase
RAF: v-raf murine sarcoma viral oncogene homolog. Human has three RAF: CRAF, BRAF, and ARAF
RAS: rat sarcoma viral oncogene homolog. Human has three RAS: HRAS, NRAS, and KRAS (KRAS4A and KRAS4B proteins arise from alternative splicing)
RB: retinoblastoma proteins including pRB, p107, and p103
RNA: ribonucleic acid
RNAi: RNA interference
RT-PCR: reverse transcription polymerase chain reaction
SDS: sodium dodecyl sulfate
shRNA: short hairpin RNA
tRNA: transfer RNA
Acknowledgments
We thank Dr. Stuart Aaronson for human melanoma cell lines. This work was supported by Bill Walter III Melanoma Research Fund, Harry J. Lloyd Charitable Trust, and Cancer and Leukemia Group B Foundation (to J.D.).References
- 1.
andDe Parseval N T Heidmann Human endogenous retroviruses: from infectious elements to human genes. Cytogenet Genome Res,2005 318 332 - 2.
andKurth R N Bannert Beneficial and detrimental effects of human endogenous retroviruses. Int J Cancer,2009 - 3.
andAhn K H. S Kim Structural and quantitative expression analyses of HERV gene family in human tissues. Mol Cells,2009 99 103 - 4.
Buscher K et al Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res,2005 4172 4180 - 5.
Muster T et al An endogenous retrovirus derived from human melanoma cells. Cancer Res,2003 8735 8741 - 6.
Mangeney M et al Endogenous retrovirus expression is required for murine melanoma tumor growth in vivo. Cancer Res,2005 2588 2591 - 7.
Oricchio E et al Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression. Oncogene,2007 4226 4233 - 8.
Pothlichet J andM Mangeney T Heidmann Mobility and integration sites of a murine C57BL/6 melanoma endogenous retrovirus involved in tumor progression in vivo. Int J Cancer,2006 1869 1877 - 9.
Serafino A et al The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. Exp Cell Res,2009 849 862 - 10.
andDong J C. L Schwab Simultaneous knockdown of mutant BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis . Treatment of Metastatic Melanoma, ed. R.M. R.2011 InTech.149 182 - 11.
Li Z et al Expression of HERV-K correlates with status of MEK-ERK and Cancer Invest,16INK4A 16ICDK4 pathways in melanoma cells.2010 p. 1031-7. - 12.
Voisset C andR. A Weiss D. J Griffiths Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev,2008 157 196 table of contents. - 13.
Blomberg J et al Classification and nomenclature of endogenous retroviral sequences (ERVs): problems and recommendations. Gene,2009 115 123 - 14.
Lee E et al Landscape of somatic retrotransposition in human cancers. Science,2012 967 971 - 15.
Beimforde N et al Molecular cloning and functional characterization of the human endogenous retrovirus K113. Virology,2008 216 225 - 16.
Turner G et al Insertional polymorphisms of full-length endogenous retroviruses in humans. Curr Biol,2001 1531 1535 - 17.
Lower R et al Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci U S A,1993 4480 4484 - 18.
Seifarth W et al Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray. J Virol,2005 341 352 - 19.
Kalter S. S et al Brief communication: C-type particles in normal human placentas. J Natl Cancer Inst,1973 1081 1084 - 20.
andTchenio T T Heidmann Defective retroviruses can disperse in the human genome by intracellular transposition. J Virol,1991 2113 2118 - 21.
Macfarlan T. S et al Embryonic stem cell potency fluctuates with endogenous retrovirus activity. Nature,2012 57 63 - 22.
Jones R. B et al HIV-1 infection induces retrotransposition of LINE-1 elements. Retrovirology,2009 suppl 2:43 - 23.
Drewlo S et al C-Terminal truncations of syncytin-1 (ERVWE1 envelope) that increase its fusogenicity. Biol Chem,2006 1113 1120 - 24.
Rotolo S et al Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells. Int J Cancer,2005 164 169 - 25.
Zhao Y et al Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem Biophys Res Commun,2008 509 513 - 26.
Li J et al Simultaneous Inhibition of MEK and CDK4 Leads to Potent Apoptosis in Human Melanoma Cells. Cancer Invest,2009 - 27.
Mettling C et al Galphai protein-dependant extracellular signal-regulated kinase-1/2 activation is required for HIV-1 reverse transcription. Aids,2008 1569 1576 - 28.
Richmond-sinclair N. M et al Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, Melanoma Res,53 and p16 immunostaining in cutaneous melanomas.2008 p. 336-45. - 29.
Ghiorzo P et al Expression and localization of mutant Hum Pathol,16 proteins in melanocytic lesions from familial melanoma patients.2004 p. 25-33. - 30.
Buscher K et al Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res,2006 223 234 - 31.
Romano C. M andR. F Ramalho P. M Zanotto Tempo and mode of ERV-K evolution in human and chimpanzee genomes. Arch Virol,2006 2215 2228 - 32.
Hirschl S et al Sequence variability of retroviral particles derived from human melanoma cells melanoma-associated retrovirus. Virus Res,2007 211 215 - 33.
andTaruscio D A Mantovani Factors regulating endogenous retroviral sequences in human and mouse. Cytogenet Genome Res,2004 351 362 - 34.
Lavie L et al CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2). J Virol,2005 876 883 - 35.
Montoya-durango D. E et al Epigenetic control of mammalian LINE-1 retrotransposon by retinoblastoma proteins. Mutat Res,2009 20 28 - 36.
Cui Y et al Oncogenic B-Raf( Cancer Res,600E induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.2010 675 684 - 37.
Singh S et al The role of human endogenous retroviruses in melanoma. Br J Dermatol,2009 - 38.
Li J et al Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. Cancer Invest,2010 350 356 - 39.
Henkel J Attacking AIDS with a’cocktail’ therapy? FDA Consum,1999 12 17 - 40.
Estrada Y andJ Dong L Ossowski Positive crosstalk between ERK and Pigment Cell Melanoma Res,38 in melanoma stimulates migration and in vivo proliferation.2009 p. 66-76. - 41.
Li Z et al Expression of HERV-K Correlates With Status of MEK-ERK and Cancer Invest,16INK4A 16ICDK4 Pathways in Melanoma Cells.2010 - 42.
andLee Y. N P. D Bieniasz Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog,2007 e10